Accessibility of clinical study reports supporting medicine approvals : a cross-sectional evaluation
Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved..
OBJECTIVES: Clinical study reports (CSRs) are highly detailed documents that play a pivotal role in medicine approval processes. Though not historically publicly available, in recent years, major entities including the European Medicines Agency (EMA), Health Canada, and the US Food and Drug Administration (FDA) have highlighted the importance of CSR accessibility. The primary objective herein was to determine the proportion of CSRs that support medicine approvals available for public download as well as the proportion eligible for independent researcher request via the study sponsor.
STUDY DESIGN AND SETTING: This cross-sectional study examined the accessibility of CSRs from industry-sponsored clinical trials whose results were reported in the FDA-authorized drug labels of the top 30 highest-revenue medicines of 2021. We determined (1) whether the CSRs were available for download from a public repository, and (2) whether the CSRs were eligible for request by independent researchers based on trial sponsors' data sharing policies.
RESULTS: There were 316 industry-sponsored clinical trials with results presented in the FDA-authorized drug labels of the 30 sampled medicines. Of these trials, CSRs were available for public download from 70 (22%), with 37 available at EMA and 40 at Health Canada repositories. While pharmaceutical company platforms offered no direct downloads of CSRs, sponsors confirmed that CSRs from 183 (58%) of the 316 clinical trials were eligible for independent researcher request via the submission of a research proposal. Overall, 218 (69%) of the sampled clinical trials had CSRs available for public download and/or were eligible for request from the trial sponsor.
CONCLUSION: CSRs were available from 69% of the clinical trials supporting regulatory approval of the 30 medicines sampled. However, only 22% of the CSRs were directly downloadable from regulatory agencies, the remaining required a formal application process to request access to the CSR from the study sponsor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Journal of clinical epidemiology - 167(2024) vom: 01. März, Seite 111263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hopkins, Ashley M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jclinepi.2024.111263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367103575 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367103575 | ||
| 003 | DE-627 | ||
| 005 | 20240326235235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jclinepi.2024.111263 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM367103575 | ||
| 035 | |a (NLM)38219810 | ||
| 035 | |a (PII)S0895-4356(24)00018-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hopkins, Ashley M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accessibility of clinical study reports supporting medicine approvals |b a cross-sectional evaluation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: Clinical study reports (CSRs) are highly detailed documents that play a pivotal role in medicine approval processes. Though not historically publicly available, in recent years, major entities including the European Medicines Agency (EMA), Health Canada, and the US Food and Drug Administration (FDA) have highlighted the importance of CSR accessibility. The primary objective herein was to determine the proportion of CSRs that support medicine approvals available for public download as well as the proportion eligible for independent researcher request via the study sponsor | ||
| 520 | |a STUDY DESIGN AND SETTING: This cross-sectional study examined the accessibility of CSRs from industry-sponsored clinical trials whose results were reported in the FDA-authorized drug labels of the top 30 highest-revenue medicines of 2021. We determined (1) whether the CSRs were available for download from a public repository, and (2) whether the CSRs were eligible for request by independent researchers based on trial sponsors' data sharing policies | ||
| 520 | |a RESULTS: There were 316 industry-sponsored clinical trials with results presented in the FDA-authorized drug labels of the 30 sampled medicines. Of these trials, CSRs were available for public download from 70 (22%), with 37 available at EMA and 40 at Health Canada repositories. While pharmaceutical company platforms offered no direct downloads of CSRs, sponsors confirmed that CSRs from 183 (58%) of the 316 clinical trials were eligible for independent researcher request via the submission of a research proposal. Overall, 218 (69%) of the sampled clinical trials had CSRs available for public download and/or were eligible for request from the trial sponsor | ||
| 520 | |a CONCLUSION: CSRs were available from 69% of the clinical trials supporting regulatory approval of the 30 medicines sampled. However, only 22% of the CSRs were directly downloadable from regulatory agencies, the remaining required a formal application process to request access to the CSR from the study sponsor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Blockbuster medicines | |
| 650 | 4 | |a Clinical study reports | |
| 650 | 4 | |a Clinical trial transparency | |
| 650 | 4 | |a Data sharing | |
| 650 | 4 | |a Data transparency | |
| 650 | 4 | |a Industry sponsored trials | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 4 | |a Regulatory decision transparency | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Modi, Natansh D |e verfasserin |4 aut | |
| 700 | 1 | |a Rockhold, Frank W |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Tammy |e verfasserin |4 aut | |
| 700 | 1 | |a Menz, Bradley D |e verfasserin |4 aut | |
| 700 | 1 | |a Veroniki, Areti-Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a McKinnon, Ross A |e verfasserin |4 aut | |
| 700 | 1 | |a Rowland, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Swain, Sandra M |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Joseph S |e verfasserin |4 aut | |
| 700 | 1 | |a Sorich, Michael J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical epidemiology |d 1991 |g 167(2024) vom: 01. März, Seite 111263 |w (DE-627)NLM012614815 |x 1878-5921 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2024 |g day:01 |g month:03 |g pages:111263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jclinepi.2024.111263 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2024 |b 01 |c 03 |h 111263 | ||